UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Generating revenue from ideas involves innovation and market understanding. Learn how to monetize your concepts effectively.
17,831 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Cava Group stunned investors with a standout first-quarter performance, sending the stock higher. But a quick rally d...
NVIDIA's earnings call surfaced a link between Meta’s AI model and stronger ad performance, igniting questions for ad...
Investors watched AST SpaceMobile tumble on launch-delay fears after a Blue Origin test setback. This piece breaks do...
AutoZone faced a sharp May drop after mixed results and rising costs. This guide breaks down the drivers, what they m...
Red Cat Holdings faced a sharp price move after news about a government contract came with unclear value. This articl...
Nexstar's chief executive warns that the era of local news funding through traditional ads may be ending. He says the...
When defense budgets shift or quarterly results miss expectations, even blue-chip stocks can move. This guide explain...
When chip stocks swing, choosing the right side matters. This guide weighs Nvidia vs AMD after the sell-off, with num...
Dell Technologies rides a surge in AI infrastructure demand, with a raised outlook and a growing AI backlog lifting t...
Cloudflare signals a bold pivot to AI-enabled edge infrastructure, reorganizing around AI and cutting roughly one-fif...
Apple stock is trading in the high 300s as traders weigh a possible rally. Here are three catalysts that could push a...